Front-Line Treatment With Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results From a Phase II Study
Urology - United States
doi 10.1016/j.urology.2015.12.007
Full Text
Open PDFAbstract
Available in full text
Categories
Date
March 1, 2016
Authors
Publisher
Elsevier BV